<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490918</url>
  </required_header>
  <id_info>
    <org_study_id>ACADEMIC</org_study_id>
    <nct_id>NCT01490918</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Acarbose Added on Top of Metformin and Sitagliptin Combination Treatment in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective To evaluate the efficacy of Acarbose add-on therapy on glucose control in&#xD;
      subjects with type 2 diabetes inadequately controlled with Metformin and Sitagliptin&#xD;
      combination therapy.&#xD;
&#xD;
      The effect of acarbose, an alpha glucosidase inhibitor as a third-line therapeutic medication&#xD;
      in subject who are inadequately controlled with metformin and DPP4 inhibitor will be&#xD;
      evaluated with multicenter, randomized, 24-week, double blinded, placebo-controlled study in&#xD;
      Korea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be assigned among 3 groups randomly at a ration of 2:2:1 to the&#xD;
      following groups and primary efficacy variable analyzed at week 16.&#xD;
&#xD;
      group 1 : acarbose placebo + metformin + sitagliptin (with switching placebo to acarbose qt&#xD;
      week 16) group 2 : acarbose + metformin + sitagliptin group 3 : acarbose + metformin placebo&#xD;
      + sitagliptin (with switching placebo to metformin at week 16)&#xD;
&#xD;
      After 16 week of treatment, all subjects in 3 groups will be treated as triple combination of&#xD;
      acarbose + metformin + sitagliptin, and diabetes related variables be collected and analyzed.&#xD;
&#xD;
        1. Primary Endpoint Changes in HbA1c (hemoglobin A1c) at 16 week from baseline between&#xD;
           group1 vs grou2&#xD;
&#xD;
        2. Secondary Endpoints (1) Changes of HbA1c at 24 week between 3 groups (2) Changed of&#xD;
           post-prandial blood glucose at 2 hour (ppg2h) at 16, 24 week&#xD;
&#xD;
      for exploratory purpose, following data will be collected and analyzed&#xD;
&#xD;
        1. continuous glucose monitoring system (CGMS) data among selected subjects in 3 groups&#xD;
&#xD;
        2. mixed meal tolerance test in only available institution. (glucose, insulin, GLP-1, GIP,&#xD;
           glucagon ) among selected subjects in group 1 and group 2&#xD;
&#xD;
        3. oxidative stress markers (8-OHdG, nitrotyrosin, CML)&#xD;
&#xD;
        4. self monitoring of blood glucose&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>placebo medication</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment</measure>
    <time_frame>baseline, 16 weeks</time_frame>
    <description>The change of glycated hemoglogin(HbA1c) from baseline to 16 weeks of treatment between Placebo + Metformin+Sitagliptin and Metformin + Sitagliptin + Acarbose group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change of HbA1c From Baseline to 24 Weeks of Treatment</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>The change of glycated hemoglogin(HbA1c) from baseline to 24 weeks of treatment between 3 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change of PPG2hr From Baseline to 24 Weeks of Treatment</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>The change of PPG2hr (post prandia blood glucose 2hr from baseline to 24 weeks of treatment between 3 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glucose During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),</measure>
    <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
    <description>Change of AUC(area under the curve) of glucose at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin During Mixed Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),</measure>
    <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
    <description>Change of AUC(area under the curve) of insulin at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Active GLP-1 at 0 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)</measure>
    <time_frame>baseline, 16 week</time_frame>
    <description>Change of active GLP-1 at 0 minute during mixed meal test at 16 week from baseline between 2 groups(group1, group2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Active GLP-1 at 120 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)</measure>
    <time_frame>baseline, 16 week</time_frame>
    <description>Change of active GLP-1 at 120 minute during mixed meal test at 16 week from baseline between 2 groups(group1, group2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glucagon During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),</measure>
    <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
    <description>Change of AUC(area under the curve) of glucagon at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Mean Glucose During CGMS Between 3 Group</measure>
    <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
    <description>Change of mean glucose of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 3 groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Variation of Glucose During CGMS Between 3 Group</measure>
    <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
    <description>Change of standard deviation of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 3 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin vs placebo + acarbose + sitagliptin)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in MAGE of Glucose During CGMS Between 2 Group(Group 1 vs Group 2),</measure>
    <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
    <description>Change of mean amplitude of glycemic excursion of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Acarbose placebo, Metformin, Sitagliptin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Acarbose placebo should be changed into real Acarbose from the 16th week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin, Metformin, Acarbose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin, Sitagliptin, Acarbose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin placebo, Sitagliptin, Acarbose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Metformin placebo should be changed into real Metformin from the 16th week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>Acarbose 50mg b.i.d at first, at the 2nd week 50mg t.i.d and the 4th week, 100mg tid.</description>
    <arm_group_label>Sitagliptin, Metformin, Acarbose</arm_group_label>
    <other_name>triple combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo acarbose</intervention_name>
    <description>acarbose placebo</description>
    <arm_group_label>Acarbose placebo, Metformin, Sitagliptin</arm_group_label>
    <other_name>dual combination (metformin+sitagliptin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo metformin</intervention_name>
    <description>metformin placebo</description>
    <arm_group_label>Metformin placebo, Sitagliptin, Acarbose</arm_group_label>
    <other_name>dual combination (acarbose + sitagliptin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with type-II diabetes mellitus;&#xD;
&#xD;
          2. Subjects aged between 20 and 80;&#xD;
&#xD;
          3. Subjects whose HbA1c ratio is between 7.0% and 10.0%;&#xD;
&#xD;
          4. Subjects who took Metformin and Sitagliptin for at least 12 weeks;&#xD;
&#xD;
          5. Subjects who were given the explanation about this clinical study and signed the&#xD;
             consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have taken drugs that are likely to affect blood glucose or who need to&#xD;
             take such drugs, e.g., glucocorticoid;&#xD;
&#xD;
          2. Subjects with severe renal diseases (men: Scr&gt;1.5 / women: Scr&gt;1.4);&#xD;
&#xD;
          3. Subjects with severe liver diseases or whose AST and ALT are at least 2.5 times higher&#xD;
             than the upper limits of normal (ULN);&#xD;
&#xD;
          4. Subjects having the case history of lactic acidosis;&#xD;
&#xD;
          5. Subjects who have the case history of myocardial infarction or unstable angina or who&#xD;
             underwent the coronary artery bypass graft 6 months before the screening test or who&#xD;
             have arrhythmia to be treated;&#xD;
&#xD;
          6. Subjects with congestive heart failures to be treated;&#xD;
&#xD;
          7. Subjects who fall into New York Heart Association (NYHA) class III or IV;&#xD;
&#xD;
          8. Subjects having the case history of acute or chronic metabolic acidosis including&#xD;
             ketoacidosis;&#xD;
&#xD;
          9. Subjects who have been pregnant or who are in the period of lactation;&#xD;
&#xD;
         10. Subjects diagnosed with malignant tumors within 5 years;&#xD;
&#xD;
         11. Subjects who are hypersensitive to Metformin, Sitagliptin and Acarbose or their&#xD;
             ingredients;&#xD;
&#xD;
         12. Subjects with inflammatory bowel diseases or intestinal ulcers or enterostenosis&#xD;
             (includes Subjects who are vulnerable to enterostenosis) or chronic enteric diseases&#xD;
             related to digestion and absorption or whose symptoms are likely to worsen due to&#xD;
             intestinal gas;&#xD;
&#xD;
         13. Subjects who participated in other clinical studies as Subjects within 60 days before&#xD;
             this study (or before taking the investigational drugs);&#xD;
&#xD;
         14. Subjects judged unfit for this study by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun-HO Yoon, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedicalExcellence</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 9, 2011</study_first_submitted>
  <study_first_submitted_qc>December 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <results_first_submitted>February 7, 2019</results_first_submitted>
  <results_first_submitted_qc>July 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2020</results_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Kun-Ho Yoon</investigator_full_name>
    <investigator_title>Professor, Medical doctor</investigator_title>
  </responsible_party>
  <keyword>Acarbose</keyword>
  <keyword>ACADEMIC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acarbose Placebo, Metformin, Sitagliptin</title>
          <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin, Metformin, Acarbose</title>
          <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Metformin Placebo, Sitagliptin, Acarbose</title>
          <description>Placebo and sitagliptin and acarbose treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks. The Metformin placebo should be changed into real Metformin from the 16th week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other cause</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acarbose Placebo, Metformin, Sitagliptin</title>
          <description>The dose of Acarbose should be 50mg b.i.d, 50mg t.i.d and 100mg t.i.d at the 18th week, the 20th week and the 24th week respectively. The Acarbose placebo should be changed into real Acarbose from the 16th week.&#xD;
Acarbose: The dose of Acarbose or its placebo should be 50mg b.i.d at first. At the 2nd week and the 4th week, it should be 50mg t.i.d and 100mg t.i.d respectively</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin, Metformin, Acarbose</title>
          <description>The group's drugs not include placebo. (Metformin, Sitagliptin, Acarbose)&#xD;
Acarbose: The dose of Acarbose or its placebo should be 50mg b.i.d at first. At the 2nd week and the 4th week, it should be 50mg t.i.d and 100mg t.i.d respectively</description>
        </group>
        <group group_id="B3">
          <title>Metformin Placebo, Sitagliptin, Acarbose</title>
          <description>The Metformin placebo should be changed into real Metformin from the 16th week.&#xD;
Acarbose: The dose of Acarbose or its placebo should be 50mg b.i.d at first. At the 2nd week and the 4th week, it should be 50mg t.i.d and 100mg t.i.d respectively</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="34"/>
            <count group_id="B4" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.55" spread="10.51"/>
                    <measurement group_id="B2" value="60.89" spread="8.8"/>
                    <measurement group_id="B3" value="60.15" spread="9.92"/>
                    <measurement group_id="B4" value="59.03" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment</title>
        <description>The change of glycated hemoglogin(HbA1c) from baseline to 16 weeks of treatment between Placebo + Metformin+Sitagliptin and Metformin + Sitagliptin + Acarbose group</description>
        <time_frame>baseline, 16 weeks</time_frame>
        <population>ITT: intention to treatment, All subject randomized to each treatment group</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks as triple combination of acarbose + metformin + sitagliptin</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo+Sitagliptin+Acarbose</title>
            <description>Placebo and sitagliptin and acarbose treatment for 16 weeks. The placebo will be changed to Metformin from the 16th week and maintained another 8 week for triple combination of metformin + sitagliptin + acarbose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment</title>
          <description>The change of glycated hemoglogin(HbA1c) from baseline to 16 weeks of treatment between Placebo + Metformin+Sitagliptin and Metformin + Sitagliptin + Acarbose group</description>
          <population>ITT: intention to treatment, All subject randomized to each treatment group</population>
          <units>% of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.1"/>
                    <measurement group_id="O2" value="-0.44" spread="0.08"/>
                    <measurement group_id="O3" value="0.84" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>primary outcome efficacy will be evaluated between group 1(placebo + metfromin + sitagliptin) and 2 (sitagliptine + metformin + acarbose)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0036</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Baselin HbA1c as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change of HbA1c From Baseline to 24 Weeks of Treatment</title>
        <description>The change of glycated hemoglogin(HbA1c) from baseline to 24 weeks of treatment between 3 groups</description>
        <time_frame>baseline, 24 weeks</time_frame>
        <population>ITT: intention to treatment, All subject randomized to each treatment group</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks as triple combination of acarbose + metformin + sitagliptin</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo+Sitagliptin+Acarbose</title>
            <description>Placebo and sitagliptin and acarbose treatment for 16 weeks. The placebo will be changed to Metformin from the 16th week and maintained another 8 week for triple combination of metformin + sitagliptin + acarbose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change of HbA1c From Baseline to 24 Weeks of Treatment</title>
          <description>The change of glycated hemoglogin(HbA1c) from baseline to 24 weeks of treatment between 3 groups</description>
          <population>ITT: intention to treatment, All subject randomized to each treatment group</population>
          <units>% of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.82"/>
                    <measurement group_id="O2" value="-0.47" spread="0.78"/>
                    <measurement group_id="O3" value="0.23" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Baseline HbA1c as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change of PPG2hr From Baseline to 24 Weeks of Treatment</title>
        <description>The change of PPG2hr (post prandia blood glucose 2hr from baseline to 24 weeks of treatment between 3 groups</description>
        <time_frame>baseline, 24 weeks</time_frame>
        <population>ITT: intention to treatment, All subject randomized to each treatment group</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo+Sitagliptin+Acarbose</title>
            <description>Placebo and sitagliptin and acarbose treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks. The Metformin placebo should be changed into real Metformin from the 16th week.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change of PPG2hr From Baseline to 24 Weeks of Treatment</title>
          <description>The change of PPG2hr (post prandia blood glucose 2hr from baseline to 24 weeks of treatment between 3 groups</description>
          <population>ITT: intention to treatment, All subject randomized to each treatment group</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" spread="3.38"/>
                    <measurement group_id="O2" value="-1.76" spread="3.53"/>
                    <measurement group_id="O3" value="0.06" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0185</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>baseline PPG2hr as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Glucose During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),</title>
        <description>Change of AUC(area under the curve) of glucose at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
        <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Glucose During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),</title>
          <description>Change of AUC(area under the curve) of glucose at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
          <units>mg min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.85" spread="2168.64"/>
                    <measurement group_id="O2" value="-743.08" spread="1278.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0356</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>baseline data as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Insulin During Mixed Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),</title>
        <description>Change of AUC(area under the curve) of insulin at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
        <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Insulin During Mixed Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),</title>
          <description>Change of AUC(area under the curve) of insulin at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
          <units>pg min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647.65" spread="3854.75"/>
                    <measurement group_id="O2" value="221.42" spread="8339.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8258</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>baseline data as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Active GLP-1 at 0 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)</title>
        <description>Change of active GLP-1 at 0 minute during mixed meal test at 16 week from baseline between 2 groups(group1, group2)</description>
        <time_frame>baseline, 16 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Active GLP-1 at 0 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)</title>
          <description>Change of active GLP-1 at 0 minute during mixed meal test at 16 week from baseline between 2 groups(group1, group2)</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.55" spread="19.01"/>
                    <measurement group_id="O2" value="-9.33" spread="31.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9217</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>baseline data as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Active GLP-1 at 120 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)</title>
        <description>Change of active GLP-1 at 120 minute during mixed meal test at 16 week from baseline between 2 groups(group1, group2)</description>
        <time_frame>baseline, 16 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Active GLP-1 at 120 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)</title>
          <description>Change of active GLP-1 at 120 minute during mixed meal test at 16 week from baseline between 2 groups(group1, group2)</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.92" spread="21.78"/>
                    <measurement group_id="O2" value="-23.36" spread="33.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>baseline data as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Glucagon During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),</title>
        <description>Change of AUC(area under the curve) of glucagon at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
        <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Glucagon During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),</title>
          <description>Change of AUC(area under the curve) of glucagon at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
          <units>min pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.22" spread="833.59"/>
                    <measurement group_id="O2" value="-1411.79" spread="1049.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>baseline data as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Mean Glucose During CGMS Between 3 Group</title>
        <description>Change of mean glucose of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 3 groups</description>
        <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks as triple combination of acarbose + metformin + sitagliptin</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Sitagliptin + Acarbose</title>
            <description>Placebo and sitagliptin and acarbose treatment for 16 weeks. The placebo will be changed to Metformin from the 16th week and maintained another 8 week for triple combination of metformin + sitagliptin + acarbose.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Mean Glucose During CGMS Between 3 Group</title>
          <description>Change of mean glucose of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 3 groups</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.81"/>
                    <measurement group_id="O2" value="-1.16" spread="0.49"/>
                    <measurement group_id="O3" value="3.22" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.292</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>baseline data as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Variation of Glucose During CGMS Between 3 Group</title>
        <description>Change of standard deviation of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 3 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin vs placebo + acarbose + sitagliptin)</description>
        <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks as triple combination of acarbose + metformin + sitagliptin</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Acarbose + Sitagliptin</title>
            <description>Placebo and sitagliptin and acarbose treatment for 16 weeks. The placebo will be changed to Metformin from the 16th week and maintained another 8 week for triple combination of metformin + sitagliptin + acarbose.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Variation of Glucose During CGMS Between 3 Group</title>
          <description>Change of standard deviation of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 3 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin vs placebo + acarbose + sitagliptin)</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="1.0"/>
                    <measurement group_id="O2" value="-0.65" spread="0.8"/>
                    <measurement group_id="O3" value="0.03" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.314</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>baseline data as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in MAGE of Glucose During CGMS Between 2 Group(Group 1 vs Group 2),</title>
        <description>Change of mean amplitude of glycemic excursion of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
        <time_frame>Visit 2(baseline) and Visit 5(16W)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo+Metformin+Sitagliptin</title>
            <description>Metformin and sitagliptin and placebo treatment for 16 weeks. Placebo was changed to acarbose at 16 week and maintained for another 8 weeks as triple combination of acarbose + metformin + sitagliptin</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin+Metformin+Acarbose</title>
            <description>Metformin and sitagliptin and acarbose treatment for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Acarbose + Sitagliptin</title>
            <description>Placebo and sitagliptin and acarbose treatment for 16 weeks. The placebo will be changed to Metformin from the 16th week and maintained another 8 week for triple combination of metformin + sitagliptin + acarbose.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in MAGE of Glucose During CGMS Between 2 Group(Group 1 vs Group 2),</title>
          <description>Change of mean amplitude of glycemic excursion of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.79" spread="15.01"/>
                    <measurement group_id="O2" value="-18.5" spread="13.23"/>
                    <measurement group_id="O3" value="2.72" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7563</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>baseline data as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <desc>total number afffected by any other adverse event : included SAEs</desc>
      <group_list>
        <group group_id="E1">
          <title>Acarbose Placebo, Metformin, Sitagliptin</title>
          <description>The dose of Acarbose should be 50mg b.i.d, 50mg t.i.d and 100mg t.i.d at the 18th week, the 20th week and the 24th week respectively. The Acarbose placebo should be changed into real Acarbose from the 16th week.&#xD;
Acarbose: The dose of Acarbose or its placebo should be 50mg b.i.d at first. At the 2nd week and the 4th week, it should be 50mg t.i.d and 100mg t.i.d respectively</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin, Metformin, Acarbose</title>
          <description>The group's drugs not include placebo. (Metformin, Sitagliptin, Acarbose)&#xD;
Acarbose: The dose of Acarbose or its placebo should be 50mg b.i.d at first. At the 2nd week and the 4th week, it should be 50mg t.i.d and 100mg t.i.d respectively</description>
        </group>
        <group group_id="E3">
          <title>Metformin Placebo, Sitagliptin, Acarbose</title>
          <description>The Metformin placebo should be changed into real Metformin from the 16th week.&#xD;
Acarbose: The dose of Acarbose or its placebo should be 50mg b.i.d at first. At the 2nd week and the 4th week, it should be 50mg t.i.d and 100mg t.i.d respectively</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>visual acuity reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>large intestinal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>toothcache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>liver function test abnormal</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus inadequate controll</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>uterine leimyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>prorteinuria</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>vitiligo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Evaluation of GIP and oxidative stress markers (8-OHdG, Nitrotyrosin) were not analyzed due to limited number of sample and technical problems leading to uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Yoon Hee Choi</name_or_title>
      <organization>The Catholic University of Korea, Seoul St Mary's Hospital</organization>
      <phone>82-2-2258-8288</phone>
      <email>choiyh@catholic.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

